Page last updated: 2024-09-05

lapatinib and tamoxifen

lapatinib has been researched along with tamoxifen in 38 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(tamoxifen)
Trials
(tamoxifen)
Recent Studies (post-2010) (tamoxifen)
1,9193051,44220,6302,2276,256

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)tamoxifen (IC50)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.46
Serine/threonine-protein kinase D3Homo sapiens (human)1
Bile salt export pumpHomo sapiens (human)10
Epidermal growth factor receptorHomo sapiens (human)3.553
Estrogen receptorHomo sapiens (human)0.9266
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)2.949
Protein kinase C gamma typeHomo sapiens (human)1
Protein kinase C beta typeHomo sapiens (human)1
Tyrosine-protein kinase LckHomo sapiens (human)8.033
Tyrosine-protein kinase FynHomo sapiens (human)1.195
Progesterone receptorHomo sapiens (human)0.1288
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)1.472
Muscarinic acetylcholine receptor M2Homo sapiens (human)7.793
Muscarinic acetylcholine receptor M4Homo sapiens (human)4.817
ATP-dependent translocase ABCB1Homo sapiens (human)6.4
Muscarinic acetylcholine receptor M5Homo sapiens (human)2.585
Alpha-2A adrenergic receptorHomo sapiens (human)1.935
Adenosine receptor A3Homo sapiens (human)3.701
Muscarinic acetylcholine receptor M1Homo sapiens (human)2.829
Steroid hormone receptor ERR1Homo sapiens (human)0.2
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)0.967
Beta-3 adrenergic receptorHomo sapiens (human)7.703
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)3.701
Protein kinase C alpha typeHomo sapiens (human)1
Alpha-2B adrenergic receptorHomo sapiens (human)3.518
Muscarinic acetylcholine receptor M3Homo sapiens (human)2.974
Substance-K receptorHomo sapiens (human)3.67
D(1A) dopamine receptorHomo sapiens (human)8.502
Prostaglandin G/H synthase 1Homo sapiens (human)4.391
Sodium-dependent noradrenaline transporter Homo sapiens (human)1.472
Thromboxane-A synthase Homo sapiens (human)0.916
Protein kinase C eta typeHomo sapiens (human)1
Histamine H2 receptorHomo sapiens (human)9.396
Alpha-1D adrenergic receptorHomo sapiens (human)4.982
5-hydroxytryptamine receptor 2AHomo sapiens (human)4.801
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.46
Adenosine receptor A2aHomo sapiens (human)7.099
Sodium-dependent serotonin transporterHomo sapiens (human)2.334
D(3) dopamine receptorHomo sapiens (human)1.072
5-hydroxytryptamine receptor 2BHomo sapiens (human)2.084
Protein kinase C iota typeHomo sapiens (human)1
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)3.701
5-hydroxytryptamine receptor 6Homo sapiens (human)2.679
Estrogen-related receptor gammaHomo sapiens (human)0.0622
Sodium-dependent dopamine transporter Homo sapiens (human)1.841
Protein kinase C epsilon typeHomo sapiens (human)1
Protein kinase C theta typeHomo sapiens (human)1
Protein kinase C zeta typeHomo sapiens (human)1
Protein kinase C delta typeHomo sapiens (human)1
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)1.2759
Platelet-activating factor acetylhydrolaseHomo sapiens (human)0.904
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)0.012
Serine/threonine-protein kinase D1Homo sapiens (human)1
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)0.967
Estrogen receptor betaHomo sapiens (human)0.7809
Sigma non-opioid intracellular receptor 1Homo sapiens (human)0.021
7-dehydrocholesterol reductaseHomo sapiens (human)0.012

Research

Studies (38)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (18.42)29.6817
2010's25 (65.79)24.3611
2020's6 (15.79)2.80

Authors

AuthorsStudies
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Liu, Y; Xu, Z; Zhao, SJ1
Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E1
Blackwell, K; Chen, S; Chu, I; Slingerland, J1
Awada, A; Cardoso, F; de Azambuja, E; Dinh, P; Gil, T; Piccart-Gebhart, M; Widakowich, C1
Boughey, JC; Brandt, KR; Degnim, AC; Dy, GK; Goetz, MP; Ingle, JN; Perez, EA; Pruthi, S; Reynolds, CA; Schomberg, PJ1
Audhuy, B; El-Hariry, I; Gardner, JP; Gore, M; Harper, P; Hawkins, R; Machiels, JP; Pétavy, F; Ravaud, A; Rolland, F; Schöffski, P; von der Maase, H; Zantl, N1
Cameron, DA; Stein, S1
Fricker, J1
Oestreicher, N1
Bono, P; Joensuu, H1
Crown, J; Duffy, MJ; O'Donovan, N1
A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M1
Batra, SK; Chen, AC; Creighton, CJ; Gutierrez, MC; Huang, C; Lopez-Tarruella, S; Massarweh, S; Migliaccio, I; Osborne, CK; Rimawi, M; Schiff, R; Wang, YC1
Ito, Y1
Alici, S; Arslan, UY; Bilici, M; Boruban, C; Buyukberber, S; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Mert, AG; Ozkan, M; Suner, A; Tarhan, MO; Unal, OU; Urakci, Z; Yaman, S; Yildiz, R1
Dorssers, LC; Foekens, JA; Godinho, MF; Look, MP; Petricoin, EF; Sieuwerts, AM; Sleijfer, S; van Agthoven, T; Wulfkuhle, JD1
Accolla, ML; Castelli, F; Celia, C; Ferrari, M; Fresta, M; Grattoni, A; Paolino, D; Sarpietro, MG1
Brown, C; De Souza, P; Fox, P; Gebski, V; Hudson, M; Lee, CK; Lord, S1
Mehta, A; Tripathy, D1
Fu, X; Giuliano, M; Klinowska, T; Morrison, G; Nanda, S; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Wang, T1
Awada, A; Bogaerts, J; Brain, E; Cardoso, F; Fumoleau, P; Hayward, L; Koch, KM; Lokiec, F; Marréaud, S; Rezai, K; Werutsky, G1
Piccart, M; Sonnenblick, A1
Abt, MA; Bruce, JS; Ghatnekar, GS; Grek, CL; Rhett, JM; Yeh, ES1
Matevossian, A; Resh, MD1
Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M1
Choi, J; Kim, A; Kim, C; Kim, J; Lee, J1
Chan, EC; Chan, JC; Lim, P; Ong, PS; Teng, PX1
Hu, Y; Lee, S; Li, L; Lin, L; Schiff, R; Tan, Y; Veeraraghavan, J; Wang, X; Wang, XS1
Kim, S; Kwon, YS; Nam, KS1
Jackson, DB; Kim, S; Lahu, G; Lesko, LJ; Soldatos, TG; Trame, MN; Vakilynejad, M1
Ito, Y; Kondo, M; Koseki, T; Tanaka, J; Yamada, S1
Acconcia, F1

Reviews

11 review(s) available for lapatinib and tamoxifen

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles

2019
Molecular targeted therapies in breast cancer: where are we now?
    The international journal of biochemistry & cell biology, 2007, Volume: 39, Issue:7-8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; ErbB Receptors; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Receptors, Estrogen; Tamoxifen; Trastuzumab

2007
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.
    Mayo Clinic proceedings, 2007, Volume: 82, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachytherapy; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Combined Modality Therapy; Cytochrome P-450 CYP2D6; Genes, erbB-2; Humans; Lapatinib; Male; Mastectomy; Pharmacogenetics; Quinazolines; Radiation Dosage; Tamoxifen; Trastuzumab; Treatment Outcome

2007
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Nature clinical practice. Oncology, 2008, Volume: 5, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab

2008
Costs of adjuvant breast cancer treatments.
    Cancer treatment and research, 2009, Volume: 151

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Health Care Costs; Humans; Lapatinib; Quinazolines; Tamoxifen; Trastuzumab

2009
[Novel targeted drug therapies in breast cancer].
    Duodecim; laaketieteellinen aikakauskirja, 2010, Volume: 126, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bevacizumab; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Tamoxifen; Trastuzumab

2010
Use of molecular markers for predicting therapy response in cancer patients.
    Cancer treatment reviews, 2011, Volume: 37, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Breast Neoplasms; Cytochrome P-450 CYP2D6; ErbB Receptors; Female; Genotype; Humans; Lapatinib; Mutation; Precision Medicine; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab

2011
[Progress of molecularly targeted therapy for breast cancer].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:4

    Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles

2012
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
    Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:1

    Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles

2014
Adjuvant systemic therapy in breast cancer: quo vadis?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms

2015

Trials

3 trial(s) available for lapatinib and tamoxifen

ArticleYear
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-10, Volume: 26, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Carcinoma, Renal Cell; Disease-Free Survival; ErbB Receptors; Female; Humans; Immunohistochemistry; Kidney Neoplasms; Lapatinib; Male; Megestrol Acetate; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Tamoxifen

2008
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer.
    British journal of cancer, 2013, Jul-09, Volume: 109, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Inflammation; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Leukocyte Count; Male; Megestrol Acetate; Middle Aged; Platelet Count; Prognosis; Quinazolines; Serum Albumin; Tamoxifen; Young Adult

2013
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).
    Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome

2014

Other Studies

24 other study(ies) available for lapatinib and tamoxifen

ArticleYear
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
    European journal of medicinal chemistry, 2021, Jan-15, Volume: 210

    Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2

2021
The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Cancer research, 2005, Jan-01, Volume: 65, Issue:1

    Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Tamoxifen

2005
San Antonio Breast Cancer Symposium.
    The Lancet. Oncology, 2009, Volume: 10, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid

2009
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
    Journal of the National Cancer Institute. Monographs, 2011, Volume: 2011, Issue:43

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles

2011
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
    Breast cancer research and treatment, 2012, Volume: 134, Issue:2

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Gene Expression; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Mucin-4; Oligonucleotide Array Sequence Analysis; Phenotype; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Statistics, Nonparametric; Tamoxifen; Transcriptome; Trastuzumab; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays

2012
Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
    Oncology, 2012, Volume: 83, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Multivariate Analysis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Turkey

2012
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
    British journal of cancer, 2012, Sep-04, Volume: 107, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Long Noncoding; RNA, Messenger; RNA, Untranslated; Signal Transduction; Tamoxifen

2012
Differential scanning calorimetry as a tool to investigate the transfer of anticancer drugs to biomembrane model.
    Current drug targets, 2013, Volume: 14, Issue:9

    Topics: Antineoplastic Agents; Biological Transport; Calorimetry, Differential Scanning; Cell Membrane; Cold Temperature; Dimyristoylphosphatidylcholine; Docetaxel; Drug Delivery Systems; Hot Temperature; Injections; Lapatinib; Liposomes; Membranes, Artificial; Neoplasms; Phospholipids; Quinazolines; Tamoxifen; Taxoids

2013
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
    Breast cancer research and treatment, 2014, Volume: 144, Issue:2

    Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Nude; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays

2014
Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.
    BMC cancer, 2015, Apr-03, Volume: 15

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Connexin 43; Drug Delivery Systems; Female; Humans; Lapatinib; Quinazolines; Tamoxifen; Tumor Necrosis Factor Receptor-Associated Peptides and Proteins

2015
Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.
    Molecular cancer, 2015, Apr-01, Volume: 14

    Topics: Acyltransferases; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Gene Amplification; Hedgehog Proteins; Humans; Lapatinib; Protein Transport; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tamoxifen

2015
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
    Nature communications, 2015, Nov-04, Volume: 6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab

2015
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Enzyme Induction; ErbB Receptors; Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; MCF-7 Cells; Metformin; Neoplasm Proteins; Neuregulin-1; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Tamoxifen; Tumor Stem Cell Assay

2016
Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:1

    Topics: Activation, Metabolic; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Synergism; Estrogen Receptor alpha; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Tamoxifen

2017
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
    Breast cancer research : BCR, 2020, 08-08, Volume: 22, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Lapatinib; Mice; Mice, Nude; Oncogene Proteins, Fusion; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Tamoxifen; Xenograft Model Antitumor Assays

2020
Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway.
    Biochemical pharmacology, 2021, Volume: 190

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Receptor, ErbB-2; Signal Transduction; Tamoxifen; Trastuzumab

2021
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development.
    Clinical and translational science, 2022, Volume: 15, Issue:4

    Topics: Cardiotoxicity; Doxorubicin; Drug Development; Drug-Related Side Effects and Adverse Reactions; Humans; Lapatinib; Paroxetine; Patient-Centered Care; Tamoxifen; Trastuzumab

2022
Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database.
    Anticancer research, 2022, Volume: 42, Issue:9

    Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Japan; Lapatinib; Pharmacovigilance; Tamoxifen

2022
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
    International journal of molecular sciences, 2022, Sep-21, Volume: 23, Issue:19

    Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen

2022